Evommune, Inc.

Evommune's EVO756 Misses Primary Endpoint in Phase 2b Chronic Spontaneous Urticaria Trial, Pivots to Atopic Dermatitis and Migraine

- Evommune's oral MRGPRX2 antagonist EVO756 failed to meet the primary endpoint of mean change in UAS7 at 12 weeks in a Phase 2b trial of 160 moderate-to-severe antihistamine-refractory CSU patients. - The company confirmed EVO756 was safe and well-tolerated at all doses tested and will discontinue CSU development while advancing the drug in atopic dermatitis and migraine. - Top-line Phase 2b data for EVO756 in atopic dermatitis is expected in Q3 2026, with a Phase 2b migraine prophylaxis trial initiating patient dosing imminently. - Evommune's IL-18BP fusion protein EVO301 recently reported positive Phase 2a proof-of-concept data in atopic dermatitis and will advance into a robust Phase 2b trial.